Storied CRISPR gene editing pioneer Editas Medicine $EDIT is in advanced discussions regarding the sale of the preclinical oncology lineup in its pipeline as the biotech works through a makeover of the company, its executive team and the drugs it hopes to take through the clinic, Endpoints News has learned.
Cancer drugs sit on the bottom rung of the totem pole in Editas’ R&D group, but includes the iNK treatment EDIT-202, which was recently touted by the biotech as a therapy that featured “double knock-in and double knock-out edits.” The preclinical profile of the natural killer candidate offered a shot at proving greater durability and persistence for an allogeneic — or off-the-shelf approach — against solid tumors, one of the holy grails in drug R&D these days.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
SIGN UP
LOG IN
